DPP4 and obesity disorder: DPP-4 inhibitors cases, compared to GLP-1 RA cases, were older (mean age 62.5 years vs. 57.4 years, respectively), more often male (51.5% vs. 44.6%), had lesser history of recent psychiatric disorders (56.7% vs. 67.7%), and had lesser history of obesity (23.5% vs. 51.3%; Supplementary Table S3).